PROVIDENCE – Technology firm 121Nexus, an alumnus of the Betaspring accelerator program, officially launched its new track-and-trace technology for the medical device industry at the DEMO Enterprise Conference in San Francisco on April 3.
MDDTrack helps manufacturers better manage product recalls and comply with the Food and Drug Administration’s unique device identification regulations for medical devices. The system assigns a unique URL or website to each medical device, leveraging the ability of the Web to provide up-to-date information in a variety of formats. The URL is deployed as a printed URL and corresponding QR code on the device packaging, which a health care professional can scan to get product information and view any real-time safety notifications.
The MDDTrack platform is one of three cloud-based track-and-trace technologies developed by 121Nexus, which also offers the PharTrack system for pharmaceutical companies and the IFUTrack digital publishing platform for medical device and diagnostic instruction manuals.
121Nexus Co-Founder and CEO Foster Sayers and Co-Founder and Chief Technology Officer Albert Ho presented the MDDTrack demo to conference attendees and viewers around the world who watched the live stream of the event. 121nexus was one of 26 companies invited to present this year at DEMO Enterprise, a worldwide conference and launchpad series focused on emerging technologies and new products.
“Today health care professionals don’t have the means to know if a product is under recall at the time of surgery,” said Sayers. “Making MDDTrack a new standard will ensure that a product under recall at the time of surgery is never again implanted in a patient.”
In December, 121Nexus was one of seven Rhode Island companies awarded a grant during the first round of the Innovate Rhode Island Small Business Fund, which helps defray the cost of applying for federal Small Business Innovation Research or Small Business Technology Transfer grants and matches existing Phase I SBIR/STTR awards. The company is now pursuing a Phase II grant to support the commercialization of MDDTrack.